Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR lung cancer
Adding zipalertinib to platinum-pemetrexed chemotherapy significantly improved progression-free survival in patients receiving first-line treatment for advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. have announced promising results from a Phase 3 trial evaluating the combination of zipalertinib, a targeted therapy, and chemotherapy in first-line treatment of patients with non-small cell lung cancer (NSCLC) carrying the EGFR exon 20 insertion mutation.
The REZILIENT3 trial, presented at the World Conference on Lung Cancer in Seoul, South Korea, met its primary endpoint of progression-free survival. The combination therapy provided a median progression-free survival improvement of 6.0 months compared to chemotherapy alone, with a hazard ratio of 0.50 (95% CI, 0.34-0.73; P=0.00015).
Median progression-free survival was 14.5 months for the combination versus 8.5 months for chemotherapy alone. The trial enrolled 279 advanced NSCLC patients with the specific genetic mutation, randomly assigning them to receive either the combination therapy or chemotherapy alone.
Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
